TWI722576B - 用於Ｔ細胞活化之突觸（ｓｙｎＴａｃ）多肽類及彼等之用途 - Google Patents

用於Ｔ細胞活化之突觸（ｓｙｎＴａｃ）多肽類及彼等之用途 Download PDF

Info

Publication number
TWI722576B
TWI722576B TW108133859A TW108133859A TWI722576B TW I722576 B TWI722576 B TW I722576B TW 108133859 A TW108133859 A TW 108133859A TW 108133859 A TW108133859 A TW 108133859A TW I722576 B TWI722576 B TW I722576B
Authority
TW
Taiwan
Prior art keywords
polypeptide
mhc
cases
type
multimeric
Prior art date
Application number
TW108133859A
Other languages
English (en)
Chinese (zh)
Other versions
TW201946933A (zh
Inventor
羅納德 西德爾三世
羅多弗 加帕洛
布蘭登 席勒瑞奇
史考特 加佛士
史蒂芬 艾爾莫
Original Assignee
耶奇華大學艾柏特艾因斯坦醫學院
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 耶奇華大學艾柏特艾因斯坦醫學院 filed Critical 耶奇華大學艾柏特艾因斯坦醫學院
Publication of TW201946933A publication Critical patent/TW201946933A/zh
Application granted granted Critical
Publication of TWI722576B publication Critical patent/TWI722576B/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW108133859A 2014-06-18 2015-06-17 用於Ｔ細胞活化之突觸（ｓｙｎＴａｃ）多肽類及彼等之用途 TWI722576B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462013715P 2014-06-18 2014-06-18
US62/013,715 2014-06-18
PCT/US2015/035777 WO2015195531A2 (en) 2014-06-18 2015-06-15 Syntac polypeptides and uses thereof
WOPCT/US15/35777 2015-06-15

Publications (2)

Publication Number Publication Date
TW201946933A TW201946933A (zh) 2019-12-16
TWI722576B true TWI722576B (zh) 2021-03-21

Family

ID=54936224

Family Applications (3)

Application Number Title Priority Date Filing Date
TW108133859A TWI722576B (zh) 2014-06-18 2015-06-17 用於Ｔ細胞活化之突觸（ｓｙｎＴａｃ）多肽類及彼等之用途
TW110108178A TWI795740B (zh) 2014-06-18 2015-06-17 用於Ｔ細胞活化之突觸（ｓｙｎＴａｃ）多肽類及彼等之用途
TW104119612A TWI696633B (zh) 2014-06-18 2015-06-17 用於Ｔ細胞活化之突觸（ｓｙｎＴａｃ）多肽類及彼等之用途

Family Applications After (2)

Application Number Title Priority Date Filing Date
TW110108178A TWI795740B (zh) 2014-06-18 2015-06-17 用於Ｔ細胞活化之突觸（ｓｙｎＴａｃ）多肽類及彼等之用途
TW104119612A TWI696633B (zh) 2014-06-18 2015-06-17 用於Ｔ細胞活化之突觸（ｓｙｎＴａｃ）多肽類及彼等之用途

Country Status (16)

Country Link
US (5) US20170058015A1 (enExample)
EP (3) EP3480213B1 (enExample)
JP (4) JP6652932B2 (enExample)
KR (1) KR102252119B1 (enExample)
CN (3) CN106456733B (enExample)
AU (3) AU2015277460B2 (enExample)
CA (1) CA2947489A1 (enExample)
DK (2) DK3480213T3 (enExample)
ES (2) ES2767259T3 (enExample)
HU (2) HUE048076T2 (enExample)
IL (3) IL248979B (enExample)
PL (2) PL3480213T3 (enExample)
PT (2) PT3480213T (enExample)
SG (2) SG10202006338UA (enExample)
TW (3) TWI722576B (enExample)
WO (1) WO2015195531A2 (enExample)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105121715B (zh) 2012-12-11 2018-10-26 艾伯特叶史瓦大学爱因斯坦医学院 高通量受体:配体鉴定方法
EP3423108A4 (en) * 2016-03-02 2019-10-02 Cue Biopharma, Inc. T CELL MODULATING MULTIPLE POLYPEPTIDES AND METHOD OF USE THEREOF
CA3014466A1 (en) * 2016-03-03 2017-09-08 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
CA3022331A1 (en) * 2016-05-18 2017-11-23 Albert Einstein College Of Medicine, Inc. Variant pd-l1 polypeptides, t-cell modulatory multimeric polypeptides, and methods of use thereof
CN109475628A (zh) * 2016-05-18 2019-03-15 库尔生物制药有限公司 T细胞调节性多聚体多肽及其使用方法
CA3033105A1 (en) * 2016-08-11 2018-02-15 The Council Of The Queensland Institute Of Medical Research Immune-modulating compounds
AU2017379900B2 (en) 2016-12-22 2024-12-05 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
WO2018129474A1 (en) * 2017-01-09 2018-07-12 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
EP3596118B1 (en) * 2017-03-15 2024-08-21 Cue Biopharma, Inc. Combination of multimeric fusion polypeptides and immune checkpoint inhibitor for treating hpv-associated cancer
WO2018187190A1 (en) * 2017-04-06 2018-10-11 Albert Einstein College Of Medicine, Inc. Precision activation of hiv-specific ctls to eliminate reactived latent t cells
IL270835B2 (en) * 2017-06-12 2025-01-01 Sinai Health Sys Allograft tolerance without the need for systemic immunosuppression
CN107266581B (zh) * 2017-06-13 2021-07-09 四川大学 藏猪il-12重组质粒增强pcv2疫苗免疫佐剂的制备方法及应用
IL297361B2 (en) * 2017-09-07 2024-07-01 Cue Biopharma Inc Multimeric t-cell modulatory polypeptides and methods of use thereof
WO2019051126A1 (en) * 2017-09-07 2019-03-14 Cue Biopharma, Inc. ANTIGEN PRESENTING POLYPEPTIDES COMPRISING CHEMICAL CONJUGATION SITES AND METHODS OF USE THEREOF
JP2021500855A (ja) * 2017-09-07 2021-01-14 キュー バイオファーマ， インコーポレイテッド 抗原提示ポリペプチドおよびその使用方法
WO2019051127A1 (en) 2017-09-07 2019-03-14 Cue Biopharma, Inc. MULTIMER MODULATOR POLYPEPTIDE OF LYMPHOCYTE T HAVING CONJUGATION SITES AND METHODS OF USE THEREOF
AR114294A1 (es) * 2017-11-30 2020-08-19 Grifols Diagnostic Solutions Inc Inmunoensayos y proteínas de diseño para la monitorización de tratamientos con anticuerpos contra los inhibidores de puntos de control inmunológicos pd-1 y pd-l1
WO2019139896A1 (en) 2018-01-09 2019-07-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
SMT202500038T1 (it) 2018-03-24 2025-03-12 Regeneron Pharma Topi o ratti geneticamente modificati per la generazione di anticorpi terapeutici contro complessi peptide-mhc, metodi di produzione e loro utilizzo
US20220047710A1 (en) * 2018-09-12 2022-02-17 Washington University Single chain constructs
WO2020118447A1 (en) * 2018-12-13 2020-06-18 Sinai Health System Immunomodulatory cells and uses thereof
BR112021011838A2 (pt) * 2018-12-19 2021-08-31 Cue Biopharma, Inc. Peptídeos multiméricos moduladores de células t e métodos de uso destes
TWI856047B (zh) * 2018-12-19 2024-09-21 美商信號生物製藥公司 多聚體ｔ細胞調節多肽及其使用方法
WO2020132368A1 (en) * 2018-12-19 2020-06-25 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof
EP3935080A4 (en) * 2019-03-06 2023-04-05 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
EP3935079A4 (en) * 2019-03-06 2023-03-22 Cue Biopharma, Inc. T LYMPHOCYTE MODULATOR ANTIGEN PRESENTING POLYPEPTIDES AND METHODS OF USE THEREOF
CN118852456A (zh) * 2019-05-29 2024-10-29 Cue生物制药股份有限公司 多聚体t细胞调节多肽及其使用方法
EP3986448A4 (en) * 2019-06-19 2023-07-12 Cue Biopharma, Inc. MULTIMERIC T-CELL-MODULATING POLYPEPTIDES AND METHODS OF USE THEREOF
EP4030897A4 (en) * 2019-09-20 2023-10-18 Cue Biopharma, Inc. T-cell modulatory polypeptides and methods of use thereof
JP2023500574A (ja) * 2019-10-23 2023-01-10 キュー バイオファーマ， インコーポレイテッド Ｔ細胞調節性キメラ分子及びその使用方法
US20210188934A1 (en) 2019-12-20 2021-06-24 Regeneron Pharmaceuticals, Inc. Novel il2 agonists and methods of use thereof
US20230076204A1 (en) * 2020-02-18 2023-03-09 Institute For Systems Biology Single chain trimer mhc class ii nucleic acids and proteins and methods of use
WO2021168388A1 (en) * 2020-02-21 2021-08-26 3T Biosciences, Inc. Yeast display libraries, associated compositions, and associated methods of use
WO2021178975A1 (en) * 2020-03-06 2021-09-10 Albert Einstein College Of Medicine A method to generate chimeric antigen receptor (car) t-cells (car-t cells) from pathogen-specific cytotoxic lymphocytes to enable the subsequent in vivo modulation of their functional activity
EP4149534A4 (en) 2020-05-12 2024-09-04 Cue Biopharma, Inc. MULTIMERIC POLYPEPTIDES MODULATING T CELLS AND METHODS OF USE THEREOF
JP2023525822A (ja) * 2020-05-12 2023-06-19 エルジー・ケム・リミテッド 多量体ｔ細胞調節性ポリペプチド及びその使用方法
WO2022056015A1 (en) * 2020-09-09 2022-03-17 Cue Biopharma, Inc. Mhc class ii t-cell modulatory multimeric polypeptides and methods of use thereof
WO2022056014A1 (en) 2020-09-09 2022-03-17 Cue Biopharma, Inc. Mhc class ii t-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereof
CN112852744A (zh) * 2021-01-27 2021-05-28 河南省华隆生物技术有限公司 一种nk滋养层细胞及其制备方法和应用
CN112779224A (zh) * 2021-01-27 2021-05-11 河南省华隆生物技术有限公司 一种表达细胞因子组合物的nk滋养层细胞及其制备方法和应用
CN112725273A (zh) * 2021-01-27 2021-04-30 河南省华隆生物技术有限公司 一种nk细胞及其制备方法和应用
CN112725284A (zh) * 2021-01-27 2021-04-30 河南省华隆生物技术有限公司 一种nk滋养层细胞及其应用
CN117222421A (zh) * 2021-03-19 2023-12-12 Cue生物制药股份有限公司 T细胞调节多肽和其使用方法
AU2022253266A1 (en) * 2021-04-07 2023-11-23 Repertoire Immune Medicines, Inc. Peptide-mhc-immunoglobulin multimers and methods of use thereof
EP4334453A4 (en) * 2021-05-07 2025-09-03 Inst Systems Biology SINGLE-CHAIN TRIMER MHC CLASS I NUCLEIC ACIDS AND PROTEINS AND METHODS OF USE THEREOF
WO2023022965A2 (en) 2021-08-16 2023-02-23 Regeneron Pharmaceuticals, Inc. Novel il27 receptor agonists and methods of use thereof
EP4387644A4 (en) * 2021-08-20 2025-10-08 3T Biosciences Inc PEPTIDE-HLA-B*35 LIBRARIES, RELATED COMPOSITIONS AND RELATED METHODS OF USE
EP4460515A1 (en) * 2022-01-03 2024-11-13 Aarhus Universitet Proteinaceous compound for generating specific cytotoxic t-cell effect
WO2023205728A2 (en) * 2022-04-21 2023-10-26 Institute For Systems Biology Soluble single-chain dimers from cleavable single chain trimers
WO2023240124A1 (en) 2022-06-07 2023-12-14 Regeneron Pharmaceuticals, Inc. Pseudotyped viral particles for targeting tcr-expressing cells
CA3258639A1 (en) 2022-06-07 2023-12-14 Regeneron Pharma Multispecific molecules to modulate T lymphocyte activity, and their uses
WO2024059740A1 (en) * 2022-09-14 2024-03-21 Synthego Corporation Genetically modified polynucleotides and cells expressing modified mhc proteins and uses thereof
US20250339384A1 (en) 2023-01-27 2025-11-06 Regeneron Pharmaceuticals, Inc. Modified rhabdovirus glycoproteins and uses thereof
IL322890A (en) 2023-02-28 2025-10-01 Regeneron Pharma Multispecific molecules containing an MHC-peptide complex containing an MHC domain and an antigenic peptide and a partially targeted immune cell antigen
WO2025081106A2 (en) * 2023-10-12 2025-04-17 Vanderbilt University Nanobody vaccine compositions

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110318380A1 (en) * 2008-10-01 2011-12-29 Dako Denmark A/S MHC Multimers in Cancer Vaccines and Immune Monitoring

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
DE69233013T2 (de) 1991-08-20 2004-03-04 The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
CA2592997A1 (en) 1992-12-03 1994-06-09 Genzyme Corporation Pseudo-adenovirus vectors
JP3532566B2 (ja) 1993-06-24 2004-05-31 エル． グラハム，フランク 遺伝子治療のためのアデノウイルスベクター
JP3875990B2 (ja) 1993-10-25 2007-01-31 カンジ，インコーポレイテッド 組換えアデノウイルスベクターおよび使用方法
US5869270A (en) * 1996-01-31 1999-02-09 Sunol Molecular Corporation Single chain MHC complexes and uses thereof
US6211342B1 (en) * 1996-07-18 2001-04-03 Children's Hospital Medical Center Multivalent MHC complex peptide fusion protein complex for stimulating specific T cell function
US20050003431A1 (en) * 1996-08-16 2005-01-06 Wucherpfennig Kai W. Monovalent, multivalent, and multimeric MHC binding domain fusion proteins and conjugates, and uses therefor
US7078387B1 (en) 1998-12-28 2006-07-18 Arch Development Corp. Efficient and stable in vivo gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors
US6287860B1 (en) 2000-01-20 2001-09-11 Isis Pharmaceuticals, Inc. Antisense inhibition of MEKK2 expression
CA2440773A1 (en) * 2001-03-14 2002-09-19 Dakocytomation Denmark A/S Novel mhc molecule constructs, and methods of employing these constructs for diagnosis and therapy, and uses of mhc molecules
DE102004014983A1 (de) * 2004-03-26 2005-10-20 Univ Stuttgart Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
EP1996937A4 (en) 2006-03-06 2009-04-08 Amunix Inc GENETIC PACKS AND USES THEREOF
US8518697B2 (en) * 2006-04-04 2013-08-27 Washington University Single chain trimers and uses therefor
EP2361930A3 (en) * 2007-03-26 2011-10-26 Dako Denmark A/S Multimers of MHC-peptide complexes and uses thereof in Borrelia infectious diseases
BRPI0815416A2 (pt) 2007-08-15 2014-10-21 Amunix Inc Composições e métodos para modificar propriedades de polipeptídeos biologicamente ativos
WO2010091122A1 (en) 2009-02-03 2010-08-12 Amunix, Inc. Extended recombinant polypeptides and compositions comprising same
US8956619B2 (en) * 2011-10-25 2015-02-17 University Of Maryland, Baltimore County Soluble CD80 as a therapeutic to reverse immune supression in cancer patients
BR112015011111A2 (pt) * 2012-11-30 2017-11-14 Roche Glycart Ag proteína multifuncional e formulação farmacêutica
WO2019051127A1 (en) * 2017-09-07 2019-03-14 Cue Biopharma, Inc. MULTIMER MODULATOR POLYPEPTIDE OF LYMPHOCYTE T HAVING CONJUGATION SITES AND METHODS OF USE THEREOF
WO2019139896A1 (en) * 2018-01-09 2019-07-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110318380A1 (en) * 2008-10-01 2011-12-29 Dako Denmark A/S MHC Multimers in Cancer Vaccines and Immune Monitoring

Also Published As

Publication number Publication date
KR102252119B1 (ko) 2021-05-17
IL248979B (en) 2020-06-30
JP2020072733A (ja) 2020-05-14
HUE048076T2 (hu) 2020-07-28
EP3157552A4 (en) 2017-11-22
AU2019203442A1 (en) 2019-06-06
TWI795740B (zh) 2023-03-11
KR20170030484A (ko) 2017-03-17
CN113248624A (zh) 2021-08-13
IL266570A (en) 2019-07-31
PL3480213T3 (pl) 2020-05-18
CA2947489A1 (en) 2015-12-23
AU2019203442B2 (en) 2021-04-08
IL266570B (en) 2020-06-30
BR112016027897A2 (pt) 2017-10-24
PT3157552T (pt) 2020-01-22
AU2015277460A1 (en) 2016-11-24
JP6652932B2 (ja) 2020-02-26
ES2770330T3 (es) 2020-07-01
EP3483179B1 (en) 2020-09-16
HUE047255T2 (hu) 2020-04-28
DK3480213T3 (da) 2020-02-17
DK3157552T3 (da) 2020-01-13
EP3480213A1 (en) 2019-05-08
SG11201609876TA (en) 2017-01-27
TW202124435A (zh) 2021-07-01
US20200377569A1 (en) 2020-12-03
IL248979A0 (en) 2017-01-31
JP2022046544A (ja) 2022-03-23
ES2767259T3 (es) 2020-06-17
CN106456733B (zh) 2021-03-16
TWI696633B (zh) 2020-06-21
JP2020022491A (ja) 2020-02-13
WO2015195531A3 (en) 2016-02-25
WO2015195531A2 (en) 2015-12-23
AU2015277460B2 (en) 2020-10-08
AU2021204594B2 (en) 2024-05-09
US20210238254A1 (en) 2021-08-05
JP6995151B2 (ja) 2022-02-21
EP3480213B1 (en) 2019-11-13
JP2017519491A (ja) 2017-07-20
IL275307A (en) 2020-07-30
PT3480213T (pt) 2020-02-04
US20170058015A1 (en) 2017-03-02
SG10202006338UA (en) 2020-08-28
EP3483179A1 (en) 2019-05-15
JP6652680B2 (ja) 2020-02-26
AU2021204594A1 (en) 2021-07-29
TW201946933A (zh) 2019-12-16
US20180282392A1 (en) 2018-10-04
CN113248624B (zh) 2025-02-07
CN113248623A (zh) 2021-08-13
PL3157552T3 (pl) 2020-05-18
TW201613966A (en) 2016-04-16
US20210047384A1 (en) 2021-02-18
IL275307B (en) 2022-03-01
CN106456733A (zh) 2017-02-22
EP3157552A2 (en) 2017-04-26
EP3157552B1 (en) 2019-10-23
JP7331075B2 (ja) 2023-08-22

Similar Documents

Publication Publication Date Title
JP7331075B2 (ja) ｓｙｎＴａｃポリペプチド及びその使用
HK40005537B (en) Syntac polypeptides and uses thereof
HK40005537A (en) Syntac polypeptides and uses thereof
HK40005540B (en) Syntac polypeptides and uses thereof
HK40005540A (en) Syntac polypeptides and uses thereof
HK1234664B (zh) Syntac多肽及其用途
HK1234664A1 (en) Syntac polypeptides and uses thereof
BR112016027897B1 (pt) Polipeptídeo multimérico, proteína, método para modular seletivamente a atividade de uma célula t, composição e método para inibir seletivamente a atividade e/ou reduzir o número de uma célula t autorreativa
HK1236106A1 (en) Syntac polypeptides and uses thereof
HK1236106B (en) Syntac polypeptides and uses thereof